HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An investigation into the blood-flow characteristics of telangiectatic skin lesions in systemic sclerosis using dual-wavelength laser Doppler imaging.

Abstract
Superficial telangiectases associated with systemic sclerosis may be more responsive to treatment than those deeper in the dermis. We investigated whether dual-wavelength laser Doppler imaging (LDI) is sufficiently sensitive to ascertain the distribution of blood flow within telangiectases and whether blood flow relates to telangiectatic diameter. The perfusion and diameter of 20 telangiectases were measured in superficial and deeper layers of the skin using dual-wavelength LDI. Of 20 telangiectases, 18 had higher blood flow in the red (representing deeper blood flow), rather than the green (representing superficial blood flow) wavelength images. Clinically apparent diameters correlated with those of the superficial (r = 0.61, P = 0.01), but not with the deeper blood flow images. Hence, the apparent size of telangiectases at the skin surface does not predict blood flow through the microvessel(s) at deeper levels, and thus clinically apparent size is unlikely to predict treatment response. Dual-wavelength LDI may help predict treatment response.
AuthorsA K Murray, T L Moore, C E M Griffiths, A L Herrick
JournalClinical and experimental dermatology (Clin Exp Dermatol) Vol. 34 Issue 5 Pg. 618-20 (Jul 2009) ISSN: 1365-2230 [Electronic] England
PMID19438531 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adult
  • Aged
  • Female
  • Humans
  • Laser-Doppler Flowmetry (methods)
  • Male
  • Middle Aged
  • Regional Blood Flow
  • Scleroderma, Systemic (complications)
  • Skin (blood supply)
  • Telangiectasis (etiology, pathology, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: